Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer
Authors:
- 1 March 2003
- journal article
- clinical trial
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 13 (2) , 142-147
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI: Journal of the National Cancer Institute, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.Journal of Clinical Oncology, 1998
- Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1998
- Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.Journal of Clinical Oncology, 1997
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian CancerJNCI: Journal of the National Cancer Institute, 1994
- Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trialsBritish Journal of Cancer, 1989